share_log

MiNK's INKT Cell Therapy Shows Potential For Optimal Multi-Combination For Resistant Solid Cancers At SITC 2024; PRAME-TCR INKT Overcomes Challenges From Conventional TCR-T Cells In Solid Cancers

Benzinga ·  Nov 7 10:01

AgenT-797 Combination with Checkpoint Inhibitors and Bispecific Engagers Expands Anti-Cancer Benefit

PRAME-TCR iNKT Overcomes Challenges from Conventional TCR-T Cells in Solid Cancers

NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced data from two poster presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting in Houston, Texas. The presentations showcased new data from MiNK's iNKT cell therapy programs, agenT-797 and PRAME-TCR.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment